These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28561232)

  • 1. Effect of Different Sampling Schedules on Results of Bioavailability and Bioequivalence Studies: Evaluation by Means of Monte Carlo Simulations.
    Kano EK; Chiann C; Fukuda K; Porta V
    Drug Res (Stuttg); 2017 Aug; 67(8):451-457. PubMed ID: 28561232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bioavailability and pharmacokinetic study of Cefadroxil capsules in male healthy volunteers of Pakistan.
    Rahim N; Naqvi SB; Alam M; Rasheed A; Khalique UA
    Pak J Pharm Sci; 2016 Mar; 29(2):453-9. PubMed ID: 27087092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro In Vivo Extrapolation and Bioequivalence Prediction for Immediate-Release Capsules of Cefadroxil Based on a Physiologically-Based Pharmacokinetic ACAT Model.
    Rahim N; Naqvi SBS
    AAPS PharmSciTech; 2024 May; 25(5):100. PubMed ID: 38714602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.
    Walker SE; Friesen MH
    J Pharm Pharm Sci; 1999; 2(1):15-22. PubMed ID: 10951658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Truncated area under the curve as a measure of relative extent of bioavailability: evaluation using experimental data and Monte Carlo simulations.
    Gaudreault J; Potvin D; Lavigne J; Lalonde RL
    Pharm Res; 1998 Oct; 15(10):1621-9. PubMed ID: 9794507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of outlying data in bioavailability/bioequivalence studies.
    Liu JP; Weng CS
    Stat Med; 1991 Sep; 10(9):1375-89. PubMed ID: 1925168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New guidelines for the assessment of bioavailability and bioequivalence].
    Blume H; Schug B; Tautz J; Erb K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):548-55. PubMed ID: 15887065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of the theory of the optimal sampling scheme for bioequivalence studies].
    Tod M; Petitjean O; Nicolas P
    Therapie; 1993; 48(1):7-13. PubMed ID: 8356559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products.
    Ibarra M; Valiante C; Sopeña P; Schiavo A; Lorier M; Vázquez M; Fagiolino P
    Eur J Pharm Sci; 2018 Jun; 118():176-182. PubMed ID: 29605455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of length of sampling schedule and washout interval on magnitude of drug carryover from period 1 to period 2 in two-period, two-treatment bioequivalence studies and its attendant effects on determination of bioequivalence.
    Dhariwal K; Jackson A
    Biopharm Drug Dispos; 2003 Jul; 24(5):219-28. PubMed ID: 12784322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
    Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD
    Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence study of two oral formulations of cefadroxil in healthy volunteers.
    Kano EK; Porta V; Koono EE; Schramm SG; Serra CH
    Arzneimittelforschung; 2008; 58(1):42-7. PubMed ID: 18368950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bioavailability of two cefadroxil products using serum and urine data in healthy human volunteers.
    Otoom S; Hasan M; Najib N
    Clin Exp Pharmacol Physiol; 2004 Jul; 31(7):433-7. PubMed ID: 15236630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Silico Prediction of the Absorption and Disposition of Cefadroxil in Humans using an Intestinal Permeability Method Scaled from Humanized
    Hu Y; Smith DE
    Drug Metab Dispos; 2019 Mar; 47(3):173-183. PubMed ID: 30593545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter.
    Mangas-Sanjuan V; Navarro-Fontestad C; García-Arieta A; Trocóniz IF; Bermejo M
    Eur J Pharm Sci; 2018 May; 117():193-203. PubMed ID: 29452210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Bioequivalence Evaluation of 2 Cefadroxil Suspensions in Healthy Egyptian Male Volunteers.
    Mansour NO
    Clin Pharmacol Drug Dev; 2012 Jul; 1(3):110-3. PubMed ID: 27121338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal sampling times in bioequivalence tests.
    Kong FH; Gonin R
    J Biopharm Stat; 2000 Feb; 10(1):31-44. PubMed ID: 10709799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.
    Jackson AJ
    Pharm Res; 2000 Nov; 17(11):1432-6. PubMed ID: 11205739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
    Srinivas NR
    Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.